Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.